Status:

COMPLETED

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Lead Sponsor:

University of Ulm

Conditions:

Acute Myeloid Leukemia

Eligibility:

All Genders

18-60 years

Phase:

PHASE2

PHASE3

Brief Summary

This trial is a study on all-trans retinoic acid in combination with induction and consolidation therapy as well as pegfilgrastim after consolidation therapy in younger patients with newly diagnosed a...

Detailed Description

First Induction Therapy: * Cytarabine 100 mg/m² cont. i.v. days 1-7 * Idarubicin 12 mg/m² i.v. days 1,3,5 * Etoposide 100 mg/m² i.v. days 1-3 * ± ATRA 45 mg/m² p.o. days 6-8 * ATRA 15 mg/m² p.o. days...

Eligibility Criteria

Inclusion

  • Newly diagnosed AML defined according to the World Health Organization (WHO)-classification (excluding acute promyelocytic leukemia \[APL\])
  • Ages 18-60 years
  • Written informed consent of each patient at study entry.
  • Molecular and cytogenetical diagnostics on initial bone marrow and peripheral blood specimen at the central reference laboratories

Exclusion

  • Bleeding independent of the AML
  • Acute promyelocytic leukemia
  • Uncontrollable infection
  • Participation in a concurrent clinical study
  • Insufficiency of the kidneys (creatinine \> 1.5x upper normal serum level), of the liver (bilirubin, AST or AP \> 2x upper normal serum level), severe obstructive or restrictive ventilation disorder, heart failure New York Heart Association (NYHA) III/IV
  • Severe neurological or psychiatric disorder interfering with ability to give an informed consent.
  • No consent for registration, storage and processing of the individual disease-characteristics and course.
  • Performance status WHO \> 2
  • Pregnancy

Key Trial Info

Start Date :

July 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2013

Estimated Enrollment :

920 Patients enrolled

Trial Details

Trial ID

NCT00151242

Start Date

July 1 2004

End Date

August 1 2013

Last Update

September 20 2017

Active Locations (34)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (34 locations)

1

Department of Hematology/Oncology, University Hospital Innsbruck

Innsbruck, Austria, 6020

2

Department of Internal Medicine I, Krankenhaus der Barmherzigen Schwestern

Linz, Austria, 4010

3

Medical Department III, St. Johann-Hospital

Salzburg, Austria, 5020

4

Center of Hematology and Oncology, Hanusch-Hospital

Vienna, Austria, 1140